508 related articles for article (PubMed ID: 17600645)
1. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
[TBL] [Abstract][Full Text] [Related]
2. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.
Ali HS; York P; Ali AM; Blagden N
J Control Release; 2011 Jan; 149(2):175-81. PubMed ID: 20946923
[TBL] [Abstract][Full Text] [Related]
3. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
[TBL] [Abstract][Full Text] [Related]
4. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
Loftsson T; Hreinsdóttir D; Stefánsson E
J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
Kocbek P; Baumgartner S; Kristl J
Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
[TBL] [Abstract][Full Text] [Related]
6. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS).
Friedrich I; Reichl S; Müller-Goymann CC
Int J Pharm; 2005 Nov; 305(1-2):167-75. PubMed ID: 16242276
[TBL] [Abstract][Full Text] [Related]
7. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
8. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
Sigfridsson K; Forssén S; Holländer P; Skantze U; de Verdier J
Eur J Pharm Biopharm; 2007 Sep; 67(2):540-7. PubMed ID: 17383167
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
Hanafy A; Spahn-Langguth H; Vergnault G; Grenier P; Tubic Grozdanis M; Lenhardt T; Langguth P
Adv Drug Deliv Rev; 2007 Jul; 59(6):419-26. PubMed ID: 17566595
[TBL] [Abstract][Full Text] [Related]
11. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
Kim JH; Jang SW; Han SD; Hwang HD; Choi HG
Pharmazie; 2011 Jul; 66(7):491-5. PubMed ID: 21812323
[TBL] [Abstract][Full Text] [Related]
13. A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation.
Ali HS; Khan S; York P; Shah SM; Khan J; Hussain Z; Khan BA
Pak J Pharm Sci; 2017 Sep; 30(5):1635-1643. PubMed ID: 29084684
[TBL] [Abstract][Full Text] [Related]
14. Zn-Al-NO(3)-layered double hydroxides with intercalated diclofenac for ocular delivery.
Cao F; Wang Y; Ping Q; Liao Z
Int J Pharm; 2011 Feb; 404(1-2):250-6. PubMed ID: 21093561
[TBL] [Abstract][Full Text] [Related]
15. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
Merisko-Liversidge E; Liversidge GG
Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
[TBL] [Abstract][Full Text] [Related]
16. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation.
Kesavan K; Kant S; Singh PN; Pandit JK
Curr Eye Res; 2013 Mar; 38(3):342-52. PubMed ID: 23216079
[TBL] [Abstract][Full Text] [Related]
17. New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
Fialho SL; da Silva-Cunha A
Clin Exp Ophthalmol; 2004 Dec; 32(6):626-32. PubMed ID: 15575833
[TBL] [Abstract][Full Text] [Related]
18. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
19. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions.
Verma S; Gokhale R; Burgess DJ
Int J Pharm; 2009 Oct; 380(1-2):216-22. PubMed ID: 19596059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
